The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia

NCT07287228 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Aplastic Anemia
Refractory
Relapse

Interventions

DRUG: Daratumumab

Sponsor

Institute of Hematology & Blood Diseases Hospital, China